Richmond Pharmacology's Volunteer Database Exceeds 100,000 Volunteer Registration Records

Posted:
14
April 2010

14th April 2010

Richmond Pharmacology�s Volunteer Database Exceeds100,000 Volunteer Registration Records

Richmond Pharmacology registered its 100,000th volunteer on Tuesday the 16th of February 2010, � making our Volunteer Database the UK�s single largest database for clinical trial participation.

  • VORSPRUNG

RPL recently completed the recruitment for a POC/PD trial requiring 70 patients suffering from Relapsing Remitting Multiple Sclerosis; this was done in just 6 months, which to our knowledge is the fastest ever recruitment project in this patient population. This has allowed the sponsor significantly faster decision making.RPL also recently completed the recruitment for Europe�s first paediatric clinical trial in healthy adolescent girls. Recruitment commenced within days from Ethics Committee approval and was completed in less than two weeks.RPL is currently conducting a large scale dose escalation study requiring the inclusion of 72 Japanese for a specialist anesthetic study where each participant is to be anesthetized. Our unique capability to recruit large panels of first generation Japanese male and female volunteers has made us the leading provider of these studies in Europe.

  • DURCH

From the inception of the company, the recruitment process was given an equal footing within the company through the installation of a dedicated professional recruitment team, which has been the largest and most effective of any early phase CRO in the UK along with a strong branded marketing presence within the general population.This has enabled RPL to recruit a multitude of volunteer panels including special panels such as young healthy, elderly healthy, Japanese and patients from primary and secondary care quickly and efficiently. Multiple feedback loops within our custom built database system has always allowed us to steer towards meeting out recruitment targets in time even when timelines are moved at short notice; capabilities for which RPL is well recognized within the industry in addition to our renowned First Time in Human and TQT/cardiac safety capabilities.

  • INNOVATION

Staying ahead of the competition is essential to our continuing success as a contract research organisation. This combined with a proprietary volunteer database in excess of 100,000 strong, means that we can guarantee the delivery of a variety of healthy volunteer and patient panels on time and within budget.

Book your site visit today;You can be confident that Richmond Pharmacology will always rise to the challenge!

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more